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The discovery of the epigenetic regulation of gene expression has revolutionized both our
understanding of how genomes function and approaches to the therapy of numerous
pathologies. Schistosomes are metazoan parasites and as such utilize most, if not all
the epigenetic mechanisms in play in their vertebrate hosts: histone variants, histone
tail modifications, non-coding RNA and, perhaps, DNA methylation. Moreover, we are
acquiring an increasing understanding of the ways in which these mechanisms come
into play during the complex schistosome developmental program. In turn, interest in
the actors involved in epigenetic mechanisms, particularly the enzymes that carry out
epigenetic modifications of histones or nucleic acid, as therapeutic targets has been
stimulated by the finding that their inhibitors exert profound effects, not only on survival,
but also on the reproductive function of Schistosoma mansoni. Here, we review our
current knowledge, and what we can infer, about the role of epigenetic mechanisms in
schistosome development, differentiation and survival. We will consider which epigenetic
actors can be targeted for drug discovery and what strategies can be employed to develop
potent, selective inhibitors as drugs to cure schistosomiasis.
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INTRODUCTION
Schistosomiasis is caused by flatworm parasites of the genus
Schistosoma, five species of which infect humans in 74 tropical
and sub-tropical countries. It is estimated that more than 230
million people are infected, of which 90% are in sub-Saharan
Africa (Colley et al., 2014 for review). Nearly 30 years after
its introduction the treatment and control of schistosomiasis
relies almost exclusively on praziquantel, the only drug effec-
tive against all schistosome species infecting humans. Its use has
been and remains an unquestionable success story; mass treat-
ments of school-age children in sub-Saharan Africa under the
Schistosomiasis Control Initiative (Fenwick et al., 2009) hold the
promise of a marked continent-wide reduction in disease mor-
bidity and mortality. Nevertheless, the massive use of this drug
may well-lead to the selection of resistant/tolerant parasite strains.
Episodes of drug tolerance have been reported (Doenhoff et al.,
2008; Melman et al., 2009) and can be induced readily in the
laboratory (Fallon and Doenhoff, 1994). In addition, changes
to the local genetic polymorphism of parasites following treat-
ment of the population have been detected (Norton et al., 2010;
Coeli et al., 2013), suggesting an effect of drug selection pres-
sure. Although the precise mechanism of action of praziquantel
in killing schistosomes is unknown, its initial effects include
the rapid influx of Ca2+ ions and calcium-dependent muscle
contraction and paralysis (Day et al., 1992) and this may be
mediated via its interaction with a calcium channel beta subunit
(Kohn et al., 2001). However, resistance to praziquantel may be
mediated by increased expression of the P-glycoprotein efflux
pump, which is often involved in drug resistancemechanisms, fol-
lowing exposure to praziquantel (Messerli et al., 2009). Whether
or not such reports are the harbingers of the development of resis-
tance by schistosomes toward praziquantel, reliance on a single
drug is patently untenable in the medium to long term.
Most of the current efforts to identify new drug leads for
schistosomiasis and other neglected parasitic diseases rely on the
screening of random compound libraries directly on the par-
asite maintained in culture (phenotypic screening). The recent
publication of the genome sequences of a variety of parasites
including the three main species of schistosomes that infect
humans (Berriman et al., 2009; Zhou et al., 2009; Young et al.,
2012) now means that approaches targeting specific gene prod-
ucts or pathways can be envisaged. These can include enzymes
with activities specific to the parasite, or at least not found in the
human host (e.g., Sayed et al., 2008), metabolic bottlenecks, or
molecules that are targeted in other pathologies. For these a wide
knowledge base and extensive libraries of inhibitors may already
exist that can be exploited as starting points for the development
of parasite-selective compounds. This type of approach also has
the advantage that the molecular mechanism of action of a given
compound, which is required for any new drug, is much easier to
determine than with the random screening approach. However,
both strategies are still used and both have proved fruitful sources
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of new drugs (Swinney and Anthony, 2011) although a more
recent analysis of discovery of first-in-class drugs suggests a grow-
ing predominance of target-based approaches (Eder et al., 2014).
Drug discovery is not a zero-sum game, but more a Nash equilib-
rium (Nash, 1950; Holt and Roth, 2004) in which the coexistence
of strategies is not only possible but can also be highly productive.
Schistosomes are digenean parasites that successively infect
freshwater snails (the intermediate host) and the vertebrate
definitive host. They reproduce both asexually (within the snail
host) and sexually (vertebrate host) and their life-cycle includes
four distinct morphological forms and separate sexes at the adult
worm stage (Colley et al., 2014). The complexity of schistosome
development and differentiation implies a tight control of gene
transcription at all stages of the life-cycle and that epigenetic
mechanisms are likely to play a crucial role in these processes, sug-
gesting that they are viable drug targets. In other pathologies, but
most intensively in cancer, the targeting of epigenetic processes is
increasingly exploited. Indeed, two histone deacetylase (HDAC)
inhibitors have already been approved for use and a number of
other candidate drugs are undergoing clinical trials (Arrowsmith
et al., 2012). Moreover, large libraries of compounds that affect
epigenetic actors are available for testing against parasites. Here,
we will consider which epigenetic mechanisms can be targeted
in schistosomes and what methodologies can be used to develop
parasite-selective drug leads.
EPIGENETIC MECHANISMS AS DRUG TARGETS
The term “epigenetics” envelops a variety of heritable changes
in gene expression that are linked to structural modifications
of the chromatin, without changes to the DNA sequence. These
include DNAmethylation, reversible post-translational modifica-
tions of histones, histone variants, chromatin remodeling factors
and non-coding RNAs. Viewed as potential targets, the most
readily “druggable” are the enzymes that carry out DNA methy-
lation and histone modifications, and increasingly, micro-RNAs
(miRNAs) among the non-coding RNA categories (Figure 1).
The investigation of the role of epigenetic mechanisms in the
control of gene transcription in schistosomes, and hence in bio-
logical processes like development and reproduction, is in its
early stages. Nevertheless, the knowledge so far acquired, or
inferred from the nature of schistosomes as invertebrate meta-
zoan organisms and from a detailed analysis of the epigenetic
actors encoded in their genomes, can be exploited to develop
novel therapeutic strategies. Moreover, insights into schistosome
epigenetic mechanisms has been gained from studies aimed at
developing such strategies, including for example the character-
ization of the actions of inhibitors of histone modifying enzymes
(HMEs), or from transcript knockdown studies. Here we will
review the current state of knowledge of the epigenetic appara-
tus in schistosomes, including the still disputed significance of
DNA methylation, the miRNA repertoire, the histone modify-
ing enzyme complement and the potential for the development
of novel drug treatments targeting these elements.
DNA METHYLATION
DNA methylation encompasses the methylation or hydrox-
ymethylation of cytosine residues, mainly, but not exclusively
within CpG dinucleotides (Baubec and Schübeler, 2014) and is
an important epigenetic mark associated with gene repression.
In vertebrates three DNA methyltransferases (Dnmts) establish
(Dnmt3a and Dnmt3b) and maintain (Dnmt1) DNA methyla-
tion marks. A further member of this family, Dnmt2 is primarily
a tRNAmethyltransferase with only weak DNAmethyltransferase
activity (Schaefer and Lyko, 2010). Disruption of DNA methy-
lation patterns is present in a variety of diseases, particularly in
cancer in which many oncogenic pathways lead to Dnmt1 over-
expression, an overall DNA hypomethylation concomitant with
hypermethylation of tumor suppressor genes at CpG islands in
the promoter regions. Agents that provoke DNA demethylation,
such as 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine)
have been approved for use in myelodysplastic syndrome (Yoo
and Jones, 2006), but their mode of action is complex. It
involves conversion to a triphosphate metabolite, incorporation
into DNA provoking a DNA damage response and covalent trap-
ping of Dnmt isoforms, followed by proteolysis of the Dnmts,
demethylation and the reactivation of the hypermethylated genes
(Streseman and Lyko, 2008). The cytotoxicity of the 5-aza nucle-
osides and the lack of a direct inhibitory effect on Dnmts have
led to the search for leads for new drug development. One exam-
ple is laccaic acid A, a recently developed direct DNA-competitive
inhibitor of Dnmt1 (Fagan et al., 2013).
DNA METHYLATION IN SCHISTOSOMES
The presence of functional DNA methylation marks in schisto-
some genomes is controversial. Early work in which Southern
blot analysis was carried out for selected genes after diges-
tion with methylcytosine tolerant or sensitive restriction enzyme
isoschizomers (HpaII and MspI) showed no differences in the
restriction profiles for adult male or female S. mansoni DNA
(Fantappié et al., 2001). Moreover, the methylcytosine-dependent
restriction endonuclease McrBC failed to digest S. mansoni DNA.
However, a more recent study (Geyer et al., 2011) in which
a variety of more sensitive methods including GC-MS, anti-
methylcytosine antibodies and targeted bisulfite sequencing were
used concluded that cytosine methylation was indeed present and
a hypermethylated repetitive intron within a forkhead gene was
characterized. The only DNA methyltransferase encoded in the
schistosome genome is Dnmt2. The methyltransferases usually
associated with DNA methylation; Dnmt1 and Dnmt3 orthologs
are both absent. Dnmt 2 has only weak DNA methyltransferase
activity but has robust methyltransferase activity toward tRNAAsp
and other tRNAs (Goll et al., 2006). The diverse group of animal
species (including S. mansoni and Drosophila melanogaster) that
express only Dnmt2 have very lowDNAmethylation levels (Kraus
and Reuter, 2011). However, Dnmt2 does retain some cytosine
methyltransferase activity (Hermann et al., 2003) and Geyer et al.
(2011) showed that siRNA knockdown of SmDnmt2 transcripts
reduced overall methylcytosine levels in the schistosome genome.
These authors have further suggested that cytosine methylation is
conserved throughout the phylum Platyhelminthes (Geyer et al.,
2013). Against this, a comprehensive study (Raddatz et al., 2013)
using whole-genome bisulfite sequencing showed that the S. man-
soni genome lacked a detectable DNA methylation pattern, even
at the “hypermethylated” locus identified by Geyer et al. (2011).
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FIGURE 1 | Schematic representation of the major druggable
epigenetic mechanisms. Histone modifications shown are limited to
acetylation and methylation since the enzymes (writers and erasers)
and recognition domains (readers: bromodomains) are the most
studied for drug development. Also shown are DNA methylation and
microRNAs.
Some clusters of incompletely converted cytosines were detected
outside this region, but were consistent with bisulfite deamina-
tion artifacts (Warnecke et al., 2002). However, although these
results strongly suggested that the S. mansoni genome is in
fact unmethylated, the criticism has been leveled that the life-
cycle stage analyzed, adult male worms, has the lowest level
of DNA methylation measured using an ELISA method (Geyer
et al., 2013). Notwithstanding this controversy, which will only
be resolved by genome-wide bisulfite sequencing of other life-
cycle stages, Dnmt inhibitors were found to strongly affect adult
worms, particularly in terms of the morphology of the ovaries
and in vitro egg-laying (Geyer et al., 2011). Whether or not this
is due to the inhibition of DNA or tRNA methylation, it does
suggest that Dnmt inhibitors such as 5-azacytidine may provide
the basis for developing precursors of novel anti-schistosome
drugs.
MICRO-RNAs
Non-coding (nc) RNAs include many different classes of tran-
scripts that do not code for proteins, but have various regulatory
roles in transcription, stability or translation of protein-coding
genes. Of these, miRNAs are the best characterized in terms of
their functional roles and pathological implications, as well as
therapeutic strategies targeting them (Ling et al., 2013). They
are generated from long, capped and polyadenylated transcripts
that are processed by a nuclear complex containing RNase III
(Drosha: canonical pathway) or by the mRNA splicing machin-
ery (non-canonical pathway) (Li and Rana, 2014 for review) into
60–100 nucleotide precursors that are then transported into the
cytoplasm where they are processed by the RNase Dicer into
mature, double stranded miRNAs (Figure 1). Classically, miR-
NAs regulate transcript levels through binding to the 3′UTR
regions of their target mRNAs, usually resulting in translational
inhibition or mRNA destruction. However, it is now clear that
miRNAs may have other mechanisms of action, for instance
increasing translation via the recruitment of protein complexes to
the mRNA or by binding proteins that block translation (Elring
et al., 2010). Different miRNAs have been shown to have either
tumor-suppressive (e.g., miR-15a-mIR-16-1 cluster) or onco-
genic (mIR-21, mIR-17-mIR-92 cluster, mIR-155) properties.
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Indeed, miRNAs can drive cancer: mIR 155 overexpression on
its own provokes lymphoblastic leukemia or lymphoma in trans-
genic mice (Costinean et al., 2006). In cancer therapy, the upregu-
lation of tumor-suppressive miRNAs has the advantage of simul-
taneously affecting a number of coding or non-coding genes that
are targeted by the miRNA and that may be involved in the same
or interacting pathways. A disadvantage is that a given miRNA
may have different or even opposite effects in different cell types,
depending on the expression patterns of its target genes. However,
such considerations would be less of an obstacle in the therapy
of parasitic diseases where it can be assumed that any disruption,
positive or negative, of miRNA effects would be potentially delete-
rious to the parasite. Most current therapeutic strategies targeting
miRNA in cancer are aimed at downregulating or blocking the
function of oncogenic miRNA. One example consists in the use of
antisense oligonucleotides, particularly those containing locked
nucleic acids (LNA anti-mIRs) which are bicyclic RNA analogs
in a locked configuration. One such compound, an anti-viral,
miravirsen, is in clinical trials for the treatment of hepatitis C viral
infection (Janssen et al., 2013; Lieberman and Sarnow, 2013).
SCHISTOSOME miRNAs
A survey of the available S. mansoni EST sequences (Oliveira
et al., 2011) concluded that 10.3% (21,107 sequences) match the
genome but have no protein coding potential and are therefore
possible ncRNAs. This in turn suggests that the parasite may
use a range of ncRNAs in transcriptional and translational reg-
ulation. Moreover, the presence of proteins involved in miRNA
processing (Drosha, Dicer, and Argonaute) (reviewed in Oliveira
et al., 2011) supports a role for miRNA regulation of development
and differentiation of schistosomes and explains the effectiveness
of RNAi and siRNA knockdown of transcription in the parasite
(Boyle et al., 2003). miRNAs were first identified in S. japon-
icum (Xue et al., 2008; Huang et al., 2009) in two separate studies
that demonstrated the existence of a limited number of miRNA
that are conserved in other organisms including humans and sev-
eral hundred novel miRNAs. In the second study all the novel
miRNAs (172) were identified by an inferred RNA hairpin and
many were differentially expressed during the life-cycle (Huang
et al., 2009). Deep sequencing studies (Hao et al., 2010; Wang
et al., 2010) further showed the presence of large numbers of
siRNAs derived from transposable elements, but also identified
38 novel S. japonicum miRNAs. In S. mansoni, the sequenc-
ing of a small-RNA cDNA library yielded 211 novel miRNA
candidates of which 11 were further verified by Northern blot-
ting (Simoes et al., 2011). Therefore, although further work is
necessary to validate the schistosome specific miRNAs and deter-
mine which of them are shared between schistosome species, it
is clear that these miRNAs are potential therapeutic targets. It
is of note that flatworms show a gradual loss of conserved miR-
NAs during evolution (Fromm et al., 2013), which is suggested
to be due to morphological simplification. However, they have
equally gained specific ncRNAs, including endogenous siRNAs,
which are differentially expressed during development, notably
during the sexual differentiation of female worms (Cai et al.,
2011; Sun et al., 2014). A therapeutic strategy based on LNA
anti-mIRs would have the advantage of targeting parasite-specific
sequences and hence avoiding off-target effects, but it is not yet
known whether individual miRNAs could be valid therapeutic
targets. There are several additional challenges associated with
such a strategy (Ling et al., 2013), the main ones being to ensure
bioavailability to the parasite and oral delivery, which would
require a significant effort to investigate appropriate chemical
substitutions.
POST-TRANSLATIONAL MODIFICATIONS OF HISTONES
Histone post-translational modifications are currently under the
most intensive study for drug development. The “writers” that
add groups to histone N-terminal tails, “erasers” that remove
them, or “readers” that recognize and bind them, are all potential
therapeutic targets (Figure 1). The increasing variety of possi-
ble modifications includes phosphorylation, ubiquitinylation and
sumoylation, but acetylation and methylation are the most abun-
dant, most studied and their activity is mediated by the largest
number of druggable proteins (Arrowsmith et al., 2012). Gene
regulation is effected by combinations of these histone marks,
leading to the “histone code” hypothesis (Strahl and Allis, 2000)
whereby different chromatin states are defined by specific reper-
toires of marks.
Histone acetylation is a dynamic process regulated by histone
acetyltransferases (HAT) that use acetyl-CoA as a co-factor and
transfer an acetyl residue to the ε–amino group of lysines, partic-
ularly in the N-terminal tails of histones H3 and H4. The HDAC
that remove this mark belong to four classes in mammals. Classes
I, II, and IV have structurally-related catalytic domains and a
Zn2+-dependent catalytic mechanism (Gregoretti et al., 2004).
The class III HDACs, or sirtuins, are phylogenetically unrelated
and rely on NAD+ as a co-factor (Greiss and Gartner, 2009).
Histone acetylation neutralizes the positive charge of the lysine,
leading to a more relaxed structure permitting recruitment of the
transcriptional machinery and in consequence is associated with
transcriptional activation.
Histone methyl marks are written on lysine or arginine
residues in histone tails by S-adenosylmethionine-dependent
methyltransferases and erased by two classes of demethylase,
the Jumonji family of demethylases that are 2-oxoglutarate-
dependent, or the flavin-dependent lysine-specific demethylase
1 (KDM1/LSD1) and 2 (KDM2/LSD2). Unlike acetylation, a
methyl group has no effect on the overall charge of the lysine
or arginine residue that carries it and the effects of the mark
are mediated by “reader” proteins that either compact the
nucleosomes or form complexes with other regulatory proteins.
Moreover, lysine residues can react with different reader domains
depending on their position and degree (mono-, di, -or tri-)
of methylation and can consequently integrate signal platforms
determining activation or repression of transcription (Badeaux
and Shi, 2013).
The current list of inhibitors of “Histone Modifying Enzymes”
(HMEs) approved for use in humans or in clinical trials reflects
the initial concentration in this field on the HDACs as therapeutic
targets. Of 18 such compounds, 17 are HDAC inhibitors (includ-
ing the two approved compounds, Vorinostat, and Romidepsin)
and another is a sirtuin (Sirt) 1 inhibitor (Arrowsmith et al.,
2012; West and Johnstone, 2014). Of the HDAC inhibitors in
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clinical trials some inhibit class I and II enzymes indiscrimi-
nately, whilst others are more selective. Romidepsin preferentially
inhibits the class I HDACs 1, 2, 3, and 8, whilst Vorinostat inhibits
the class II HDAC6 and HDAC8 only poorly (Arrowsmith et al.,
2012). Selectivity for a given HDAC or class may be of therapeu-
tic importance as these enzymes have different targets. HDACs
generally deacetylate both histones and other proteins. HDAC6
is not involved in epigenetic signaling at all but deacetylates
tubulin and Hsp90 (Hubbert et al., 2002; Kovacs et al., 2005),
while the only known HDAC8 substrate is SMC3, a compo-
nent of the cohesin complex (Deardorff et al., 2012). HDAC
inhibitors occupy the hydrophobic tunnel in the enzymes that
accommodates the acetyllysine substrate and coordinate the zinc
ion at the base of the tunnel, for example with a hydroxamate
grouping as for Vorinostat. Selectivity can be based on differ-
ences between the make-up and architecture of the tunnel, or
on the surface-accessible rim. However, within the cell HDACs
are often part of multi-protein complexes that may alter substrate
and inhibitor specificities compared to isolated recombinant pro-
teins (Bantscheff et al., 2011) and this remark is likely even more
pertinent in the case of other HMEs.
Of the seven mammalian NAD+-dependent class III deacety-
lases, or sirtuins (Sirt) Sirts 1, 2, 3, 6, and 7 have been shown to
possess deacetylase activity (Feldman et al., 2012), although Sirt6
is also a fatty acylase (Jiang et al., 2013). The other two sirtuins, 4
and 5 are both predominately mitochondrial. Sirt5 is a demalony-
lase and desuccinylase (Du et al., 2011) and has recently been
shown to regulate a novel lysine modification, glutarylation (Tan
et al., 2014). Sirt4 exhibits ADP-ribosyltransferase activity (Haigis
et al., 2006). Sirtuin inhibitors have been developed against Sirts
1, 2, and 3 that couple the deacetylation reaction with the cleavage
of NAD+, liberating free nicotinamide. Inhibitors can bind either
to the conserved NAD+-binding C-pocket, like nicotinamide
itself, or the acetyllysine peptide-binding cleft between the large
and small domains of the enzyme (Yuan and Mamorstein, 2012),
or both. In addition, since Sirt1 expression has been associated
with increased lifespan and memory, allosteric activators such as
resveratrol have been explored as therapeutic agents Hubbard and
Sinclair, 2014). Only one sirtuin inhibitor, selisistat, is currently
in clinical trials, however, for Huntington’s disease (Arrowsmith
et al., 2012).
HAT generally lack obvious druggable sites and few selective
inhibitors are currently available. The HAT catalytic domains
have a conserved organization around a central fold where the
acetyl-CoA cofactor binds. The peptide substrate binding site in
the only solved structure is shallow and solvent accessible, reduc-
ing its capacity to be targeted by drugs (Arrowsmith et al., 2012).
Among the inhibitors so far described are natural substances that
promiscuously bind a variety of targets (Piaz et al., 2011), or
isothiazolone covalent modifiers (Ghizzoni et al., 2009). These
latter include the more recently developed pyridoisothiazolones
that effectively inhibit cancer cell proliferation (Furdas et al.,
2011). However, a potent, selective inhibitor of the HAT EP300,
C646, has been developed that binds at the cofactor pocket and
has pro-apoptotic effects on prostate cancer cells (Bowers et al.,
2010). This indicates that at least certain HATs are valid, stan-
dalone therapeutic targets, but effective screening may depend on
the reconstitution of multi-protein complexes in which they are
active in the cell and whichmaymodulate their enzymatic activity
(Arrowsmith et al., 2012).
The proteinmethyltransferases include both lysine (KMT) and
arginine (PRMT) methyltransferases that are phylogenetically
unrelated but share the requirement for S-adenosylmethionine
as a cofactor and a cofactor binding site adjacent to the
channel that binds the peptide substrate (Arrowsmith et al.,
2012). Both these sites can be used to generate selective
and potent inhibitors for both PRMTs and KMTs (Spannhoff
et al., 2009; Dowden et al., 2010). However, in order to
screen certain of the latter enzymes, the reconstitution of pro-
tein complexes is a prerequisite. The KMT component of the
PRC2 transcription repression complex, EZH2, which methy-
lates H3K27, is inactive on its own and minimally requires the
presence of at least two members of the complex, EED and
SUZ12 (Helin and Dhanak, 2013). High-throughput screen-
ing has been carried out on a complex additionally con-
taining AEBP2 and RbAp48 proteins and has yielded highly
selective inhibitors such as GSK126, which is a promising
lead for the treatment of lymphoma (McCabe et al., 2012).
Complex recomposition is not always necessary; the H3K79
methyltransferase DOT1L requires no partner proteins and a
highly selective inhibitor, EPZ-5676, has been developed using
a structure-guided strategy, with significant activity in a rat
xenograft model of MLL-rearranged leukemia (Daigle et al.,
2013).
Histone demethylases are under increasing scrutiny as drug
targets (Hojfeldt et al., 2013). Two unrelated families of pro-
teins exert demethylase activity, the LSD family and the JMJC
domain-containing demethylases. In mammals the LSD (for
Lysine-Specific Demethylase) family comprises only two mem-
bers, but they share an amine oxidase-like domain with several
metabolic enzymes in addition to a SWIRM (SW13, RSC8, and
Moira) domain that is only found in some chromatin-associated
enzymes. These enzymes use FAD as a cofactor that binds to
one of two folded subdomains of the amine oxidase-like domain,
the other binding the substrate. However, substrate specificity
may be regulated through interactions of the SWIRM domain
with protein partners (Metzger et al., 2005). The conservation
of the amine oxidase-like domain means that some inhibitors
of monoamine oxidases, such as tranylcypromine also inhibit
LSD1 (Schenk et al., 2012), however, selectivity for the latter
can be improved in derivatives. One such inhibitor, ORY-1001,
has greatly improved selectivity for LSD1 and is entering clini-
cal trials (Maes et al., 2013). Few selective or potent inhibitors of
JMJC (Jumonji C) demethylases have yet been reported. In these
enzymes (31 familymembers in humans) the JMJC domain is cat-
alytic and the enzymatic mechanism involves two cofactors, Fe(II)
and 2-oxoglutarate, which are bound to it. Members of this fam-
ily can demethylate mono-, di- or tri-methylated lysines. Most
reported inhibitors contain metal chelating groups (analogous to
HDAC inhibitors, but the latter are poor JMJC inhibitors) that
compete with the 2-oxoglutarate cofactor. One remarkably selec-
tive inhibitor of JMJD3, an H3K27me3-specific demethylase, has
been developed using a structure-guided approach (Kruidenier
et al., 2012). This inhibitor, GSK-J1, interacts with critical amino
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acids involved in the binding of both the 2-oxoglutarate cofactor
and the histone peptide substrate, and is competitive with the for-
mer but non-competitive with the latter. It is selective for both
JMJD3 and Utx (a closely related JMJC demethylase active on
the same substrate as JMJD3) but inactive against other members
of the JMJC family. Moreover, GSK-J1 inhibits pro-inflammatory
functions of human primary macrophages, indicating a possible
therapeutic role. Moreover, a related JMJD3 inhibitor, GSK-
J4, has recently been shown to have anti-tumorigenic activity
against T-cell acute lymphoblastic leukemia (Ntziachristos et al.,
2014).
Of the “readers” of epigenetic marks, bromodomain pro-
teins, which read acetylated lysine residues, have so far attracted
the most attention as drug targets. Bromodomains are com-
posed of a characteristic antiparallel bundle of four α-helices
that binds acetyllysine in a pocket at one extremity. They were
first identified in the Drosophila gene brahma, hence the name,
and in humans 61 bromodomains have been identified in 46
proteins, some containing more than one, and belong to eight
distinct families (Hewings et al., 2012). Although the biolog-
ical roles of most bromodomain proteins remain unknown,
the connection of some of them with diseases such as cancer
is becoming clearer (Arrowsmith et al., 2012; Filippakopoulos
and Knapp, 2014). Small molecule inhibitors have been prin-
cipally been developed against the BET bromodomain family.
A triazolobenzidine (Nicodeme et al., 2010) was initially iso-
lated as an inducer of ApoA1 expression and a derivative with
enhanced activity in a reporter gene assay was only subsequently
shown to interact with the bromodomains of BET family mem-
bers BRD2, 3, and 4 using a chemoproteomic approach (Chung
et al., 2011). Following an observation that thieodiazepines could
bind to BRD4 a structure-based approach led to the devel-
opment of a novel thieno-triazolo-1′4-diazepine named JQ1
(Filippakopoulos et al., 2011). This molecule binds to the BRD4
acetyllysine site and has reduced activity against other BRDs,
but little or none toward other bromodomains. JQ1 induced
a differentiation phenotype and growth arrest in a cell line
derived from human squamous carcinoma. Since these founder
studies, further selective inhibitors of BET bromodomains
have been identified and clinical trials are ongoing, notably
for JQ1.
SCHISTOSOME HISTONE MODIFICATIONS
An in silico analysis of the schistosome genome predictions
and EST libraries (Anderson et al., 2012) showed that 21 of
the 29 histone genes predicted in the genome are expressed in
S. mansoni, the remainder being either unexpressed or having
divergent sequences. Importantly, the N-terminal tails of the
nucleosomal histones H3 and H4 are highly conserved, sug-
gesting the functional conservation of the histone marks found
in mammalian histones. The study of histone marks and their
role in schistosome development and differentiation is still in
its infancy, but studies involving inhibitors of HDACs and HATs
have demonstrated the importance of histone acetylation and
the interest of these enzymes as potential therapeutic targets.
HDAC inhibitors including Trichostatin A (TSA) blocked the
in vitro transformation of S. mansoni miracidia into primary
sporocysts in a dose-dependent manner (Azzi et al., 2009) and
this correlated with an increase in histone H4 acetylation. More
recently, the same authors showed that differences in the levels
of histone H3K9 acetylation on the promoters of genes encoding
polymorphic mucins correlated with their differential expres-
sion in parasite strains compatible or incompatible with a given
strain of the intermediate host, the freshwater snail Biomphalaria
glabrata. TSA treatment ablated these strain-specific differences
in expression (Perrin et al., 2013).
Histone acetyltransferase inhibition also has developmen-
tal consequences in schistosomes, particularly in egg matura-
tion. The schistosome ortholog of the HAT GCN5 has been
shown to acetylate H3 and H2A, and in particular H3K14
(de Moraes Maciel et al., 2008) and the CBP/P300 ortholog
SmCBP1 primarily acetylates H4 (Bertin et al., 2006; Fantappié
et al., 2008). Knockdown of either or both of these HATs in
adult schistosomes has been shown to markedly reduce the
transcription levels of the major eggshell protein p14 and to
affect egg development. Moreover, these effects are reproduced
by treating adult worm pairs with an HAT inhibitor, PU139
(Carneiro et al., 2014). After both inhibitor treatment and RNAi
to knock down transcripts of the HATs, the phenotypic effects
on egg laying and development were correlated with decreased
acetylation of H3 and H4, increased methylation at H3K27,
a marker of transcriptional repression, on the p14 proximal
promoter.
The effects of bothHDAC andHAT inhibitors on schistosomes
suggest that histone acetylation may be a legitimate therapeu-
tic target and this was further supported by a preliminary study
showing that HDAC inhibitors like TSA and valproic acid could
induce time and dose-dependent death of schistosomes (adult
worms or schistosomula larvae) in culture (Dubois et al., 2009).
Parasite death was associated with the induction of apopto-
sis in schistosomula shown by both TUNEL staining and the
activation of the effector caspases 3/7. Once more, the molecu-
lar basis of these effects was evidenced by a global increase in
histone H3 and H4 acetylation and significantly increased H4
acetylation at the proximal promoters of HDAC target genes,
correlated with an increase in their transcription. More recently,
similar effects have been observed using inhibitors of the class
III HDAC, the sirtuins (Lancelot et al., 2013). Inhibitors of
Sirtuins 1 and 2 such as salermide also induce apoptosis and
death of schistosomula in culture. Moreover, salermide induces
marked morphological alterations to the female worm genital
apparatus, the arrest of egg-laying and the separation of worm
pairs.
SCHISTOSOME HISTONE MODIFYING ENZYMES: WHICH ARE THE
BEST TARGETS?
Schistosome HDACs and HATs are clearly potential drug targets,
as are probably other HMEs, but there are several challenges that
could potentially impede drug development:
- These enzymes are evolutionarily conserved, particularly their
catalytic domains, and in order to avoid potential side effects,
inhibitors that are selective for the schistosome enzyme have to
be developed.
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Table 1 | Identity and characteristics of Schistosoma mansoni histone modifying enzymes.
HME type Class Closest human ortholog Size (aa) Substrate specificity Gene Ida
HDAC I HDAC1 517* Smp_005210
I HDAC3 418* Smp_093280
I HDAC8 440* Smp_091990
II HDAC4 291 Smp_191310
II HDAC5 701 Smp_069380
II HDAC6 1132 Smp_138770
III (Sirtuin) Sirt1 568* H1 – H3 – H4 Smp_138640
III (Sirtuin) Sirt2 337* H4K16 Smp_084140
III (Sirtuin) Sirt5 305* Smp_055090
III (Sirtuin) Sirt6 386* H3K9 – H3K56 Smp_134630
III (Sirtuin) Sirt7 517* Smp_024670
HAT GNAT GCN5 (KAT2A) 899* H3K9 – H3K14 – H3K18 H2B Smp_070190
GNAT HAT1 (KAT1) 435 H4K5 – H4K12 Smp_178700
MYST Tip60 (KAT5) 463 H2AK5 – H3K14 – H4K5 – H4K8 – H4K12 – H4K16 Smp_053140
MYST MYST1 (KAT8) 496 H4K16 Smp_194520
MYST MYST2 (KAT7) 400 H4K5 – H4K8 – H4K12 – H3 Smp_171700
MYST MYST3 (KAT6A) 971 H3K14 Smp_131320
CBP/p300 CBP/SmCBP1 (KAT3A) 2093* H2AK5 – H2BK15 – H3K14 – H3K18 – H4K5 – H4K8 Smp_105910
CBP/p300 CBP/SmCBP2 (KAT3A) 1892 H2AK5 – H2BK15 – H3K14 – H3K18 – H4K5 – H4K8 Smp_127010
TAFII250 TFIID subunit 1 2241 H3 – H4 Smp_166840
HMT SET EZH1 1026 H3K27 Smp_078900
SET MLL3 (KMT2C) 399 H3K4 Smp_070210
SET MLL3 (KMT2C) 1560 H3K4 Smp_138030
SET MLL1/4 (KMT2D) 3002 H3K4 Smp_144180
SET MLL5 (KMT2E) 751 H3K4 Smp_161010
SET C20orf11/MLL5/Ranbp9 1305 Smp_009980
SET NSD2/WHSC1 1746 H3K4 – H4K20 Smp_160700
SET NSD1/2 (KMT3B) 1343 H3K36 – H4K44 Smp_137060
SET SET8 (KMT5A) 409 H4K20 Smp_055310
SET SUV 39H2 (KMT1B) 586 H3K9 Smp_027300
SET SUV4-20H1 (KMT5C) 613 H4K20 Smp_062530
SET SETD2 1575 H3K36 Smp_133910
SET SETD1B 1720/1822 H3K4 Smp_140390
SET SETDB 918/1032 Smp_150850
SET SETMAR 250 H3K9 Smp_043580
SET SET/MYND4 782 Smp_000700
SET SET/MYND4 527 Smp_124950
SET SET/MYND5 423/429/433 Smp_121610
DOT1 DOT1L (KMT4) H3K79 Smp_165000
PRMT PRMT1 252/359/334 H4R3 Smp_029240
PRMT PRMT3 1564 Smp_127950
PRMT PRMT4/CARM1 737 H3R2 – H3R17 – H3R26 Smp_070340
PRMT PRMT5 630 H2A – H4 Smp_171150
PRMT PRMT7 755 Smp_025550
HDM KDM1 LSD1A 1043 Smp_150560
KDM1 LSD1A 916 Smp_160810
KDM1 LSD1 (KDM1) 1073 H3K4 – H3K9 Smp_162940
JmjC JMJD1B (KDM3) 273 H3K9 Smp_161410
JmjC JMJD2C (KDM4C) 1136 H3K9 – H3K36 Smp_132170
(Continued)
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Table 1 | Continued
HME type Class Closest human ortholog Size (aa) Substrate specificity Gene Ida
JmjC JMJD4 809 Smp_147870
JmjC JMJD6 839 Smp_137240
JmjC JHDM1D (KDM7) 653 H3K36 Smp_127230
JmjC Jarid (KDM5) 2372 H3K4 Smp_156290
JmjC jarid (KDM5) 1639 H3K4 Smp_019170
JmjC UTX (KDM6A) 1137 H3K27 Smp_034000
*Validated by cDNA cloning.
aGene ID according to the genome annotation.
- If selective inhibitors can be developed, the targeted HME has
to be essential to the parasite so that its inhibition is lethal.
Many HMEs have overlapping specificities (Table 1) and the
inhibition of one may be compensated by another. However, in
the case of enzymes methylating (EZH) or demethylating (Utx)
H3K27, only one isoform is present in schistosomes (Table 1),
against two in humans, suggesting that these enzymes may
represent particularly sensitive targets.
In consequence, for these particular therapeutic targets, an
approach involving both target validation, notably by transcript
knockdown (RNAi), and structural studies to determine speci-
ficities in the structure of the catalytic pocket, is essential.
The S. mansoni genome encodes 55 HMEs involved in
protein acetylation/deacetylation or methylation/demethylation
(Table 1) (Pierce et al., 2012). Some of these, including the class I
HDACs (Oger et al., 2008) and the sirtuins (Lancelot et al., 2013)
have been cloned and characterized and preliminary choices of
targets can be made based on their degree of sequence conserva-
tion. In addition, the human orthologs of several of these enzymes
are known to function only as part of a multiprotein complex as is
the case for the H3K27 methyltransferase EZH2 mentioned pre-
viously (McCabe et al., 2012). High-throughput screening of the
human enzyme has been done, using a five protein complex, but
the resources devoted to carry out such a strategy for the devel-
opment of anti-cancer therapies are not available in the case of
neglected tropical diseases. Therefore, although the schistosome
ortholog of EZH2 is a unique target, its screening will pose dif-
ficulties and it is therefore preferable to target an enzyme that is
active on its own (like the H3K79 methyltransferase DOT1L for
example Daigle et al., 2013). In addition, certain HMEs are very
large proteins (Table 1) and although the production of trun-
cated proteins containing the catalytic domain can be envisaged,
this may affect both enzyme activity and the conformation of the
catalytic pocket, limiting the relevance of screening or structural
data.
These considerations reduce the choice of viable HME tar-
gets in schistosomes, but a large number remain. Two filters
can be used to further limit the choice: the use of HME class
inhibitors to determine whether enzyme families contain poten-
tial targets and transcript knockdown using RNAi to validate
individual HMEs as stand-alone therapeutic targets. RNAi is still
the only available means to achieve targeted knockdown of gene
function in schistosomes, but its efficacy is transcript-dependent
and phenotypes are not always observed (Stefanic et al., 2010).
DEVELOPMENT OF SELECTIVE INHIBITORS AS DRUGS: THE
CHALLENGES
An illustration of the strategy that can be employed to designate
therapeutic targets is provided by the S. mansoni class I histone
deacetylase 8 (SmHDAC8). Of the class I HDACs, SmHDAC8 was
initially designated as a potential target for two reasons. First,
transcript expression levels of SmHDAC8 are higher than those
of SmHDAC1 and SmHDAC3 throughout the life cycle, notably
in adult female worms (Oger et al., 2008). It is notable that
HDAC 8 transcript levels are generally much lower than those of
HDAC1 and 3 in normal human cells, but are markedly upreg-
ulated in some cancer cell lines and tissues (Nakagawa et al.,
2007). Second, the analysis of the primary sequence of SmHDAC8
showed that it is less well-conserved compared to its human
ortholog than the other two class I enzymes. This is demonstrated
by the sequence alignment and phylogenetic analysis shown in
Figure 2. The alignment shows that the essential residues for
HDAC activity are conserved, but that the catalytic domain
sequence contains insertions and substitutions that might indi-
cate a change in architecture of the catalytic pocket, notably the
replacement of a methionine (M274) in the human HDAC8 by
a histidine (H292) in SmHDAC8. The status of SmHDAC8 as a
stand-alone therapeutic target was enhanced by the use of generic
HDAC8 inhibitors (unpublished results) and particularly by tran-
script knockdown using RNA interference (Marek et al., 2013).
The latter showed that treatment of schistosomula with double-
stranded RNA, followed by their injection i.v. into mice and
harvesting of surviving worms 35 days later, led to a reduced
worm recovery compared to mice treated with dsRNA encoding
green fluorescent protein as a control.
Whilst molecular modeling seemed to show that only the
charge difference within the catalytic pocket provided by His292
differentiated SmHDAC8 from its human counterpart, structural
analysis by X-ray crystallography demonstrated a further impor-
tant difference (Marek et al., 2013). In the schistosome enzyme,
amino acid substitutions surrounding the catalytic pocket allow
a change in the configuration of the side chain of phenylala-
nine 151. The side chain of the equivalent residue in human
HDAC8, Phe152, adopts an obligatory flipped-in conformation
that contributes to the narrow, hydrophobic tunnel accommo-
dating the substrate or inhibitors. In contrast, in SmHDAC8 this
side chain is free to adopt a flipped-out configuration, allowing
the pocket to accommodate more bulky substrates or inhibitors.
This difference, together with the charge difference, allows the
possibility of identifying selective inhibitors for the schistosome
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FIGURE 2 | Phylogenetic relationship amongst human and
Schistosome class I HDACs. Panel (A) displays a phylogenetic tree [ML,
consensus from maximum likelihood; NJ, neighbor joining; and MB, Mr
Bayes methods) built using the amino acid sequences from the catalytic
domains of class I HDACs (HDAC1, 3, and 8) present in S. mansoni
(Sm), S. japonicum (Sj), and S. haematobium (Sh) and their human (h)
orthologs. Panel (B) shows an amino acid sequence alignment
constructed with MAFFT with the class I HDACs used above. Conserved
(black background and white letters), conservative changes (gray
background and black letters) and less conservative changes (gray
background and white letters) in amino acid positions are highlighted.
Black (F151) and brown (Y99) triangles show residues that despite being
conserved present conformational differences between human and
Schistosomes HDAC8 (Marek et al., 2013). The blue triangle shows the
position of the replacement of a methionine (M274) in the human HDAC8
by a histidine (H292) in SmHDAC8 (boxed amino acids below blue
triangle). Residues that interact with the SmHDAC8 specific inhibitor
J1075 are highlighted with blue lines.
enzyme. Indeed, an in silico screen, based on the crystal struc-
ture of SmHDAC8 and involving the docking of a large number
of potential inhibitors, led to the identification of an inhibitor,
J1075 (Marek et al., 2013), which had greatly improved selectiv-
ity for SmHDAC8 compared to human class I and II HDACs.
Moreover, this inhibitor caused dose and time-dependent death
of schistosome larvae in culture via the induction of apopto-
sis. Optimization of this and other inhibitors identified by this
strategy is ongoing, and further potential drug precursors have
been identified (Stolfa et al., 2014). It is also notable that the
structural specificities of the SmHDAC8 enzyme compared to
the human ortholog are shared with HDAC8 in other flatworms,
including other schistosome species (Figure 2), Echinococcus sp.
and Clonorchis sinensis (Marek et al., 2013). Therefore, drugs
effective against S. mansoni may well be applicable to these other
species.
This example proves the concept that individual epigenetic
enzymes can be valid therapeutic targets, and that, even though
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these enzymes generally have conserved catalytic domains, suffi-
cient differences in structure can exist to allow the development
of selective inhibitors that are drug precursors. It remains to be
seen, however, whether these inhibitors can be made sufficiently
selective to preclude potentially harmful side effects and whether
they can be developed into drugs useable in a single oral dose in
humans.
CONCLUSIONS
Epigenetic processes provide a wealth of potential therapeutic
targets for the development of novel therapies against schistoso-
miasis and other parasitic diseases. Themost readily exploitable of
these targets are the HMEs, as well as perhaps Dnmt2, which lend
themselves to target-based drug discovery strategies, necessary to
ensure the development of parasite-selective drugs. A structure-
based strategy has been initiated for S. mansoniHDAC8, involving
the solution of the 3D structure of the catalytic domain and
in silico docking of potential inhibitors. However, such enzymes
can also be screened directly using random compound libraries
and high-throughput methodologies using enzyme inhibition as
the read-out. Moreover, the existing extensive libraries of HME
inhibitors can be used for phenotypic screening of compound
libraries for lethal effects on the parasite itself. In all these cases,
since the molecular mechanism of action of the drug precur-
sor is known, time will be saved in the process of optimizing
selectivity.
The remaining potential targets discussed above, notably the
histone modification readers, like bromodomain proteins, and
miRNAs, require validation as effective targets and pose greater
challenges for drug development. In order to identify the schis-
tosome bromodomain proteins, an exhaustive analysis of the
genomic data has still to be done. However, since both bro-
modomain proteins and miRNAs are under intensive investiga-
tion, particularly for the development of anti-cancer therapies,
methodologies will be developed that could be exploited and
adapted for the treatment of parasitic diseases.
Work on all the potential targets discussed here can bene-
fit from the increasing knowledge base and compound libraries
accrued, notably in the development of anti-cancer therapies.
This “piggy-backing” approach (Dissous and Grevelding, 2010)
holds great promise and can in part mitigate the relative lack of
investment in efforts to improve the control and treatment of
schistosomiasis and the other neglected parasitic diseases.
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